INOVIQ Limited will present new data further confirming the effectiveness of its proprietary exosome isolation technology, EXO-NET®, at the upcoming Annual Meeting of the International Society for Extracellular Vesicles (ISEV) in Seattle, USA from May 17-21, 2023. INOVIQ and its collaborators, including the University of Queensland and Johns Hopkins University, will present four poster and one oral presentation at ISEV2023. The presentations cover: Research completed by Associate Professor Kenneth Witwer's team at Johns Hopkins University
clearly establishes the benefits of using EXO-NET for isolating and enriching exosomes to identify biomarkers using mass spectrometry.
Data from Associate Professor Carlos Salomon's team from the Translational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group at The University of Queensland further highlight the suitability of EXO-NET for developing new multi-marker tests for ovarian cancer. The team used mass spectrometry and next generation sequencing to identify the presence of EXO-NET isolated biomarkers in the blood of women with early-stage ovarian cancer. These biomarkers were combined in an algorithm to more accurately identify women with early-stage ovarian cancer. INOVIQ will report the results of an extensive analytical validation of EXO-NET for isolating exosomes from plasma, saliva and cell-conditioned medium and the downstream analysis of exosomal microRNA, messenger RNA and proteins. INOVIQ will also present initial results on the effectiveness of its TEXO-NET product for isolation of tumour-derived exosomes. This product combines the efficiency of INOVIQ's proprietary NETs technology with the cancer-specificity of the company's SubB2M technology.